Immuno-Oncology | Specialty

Dr. Bauml on the Use of Immunotherapy in Oligometastatic NSCLC

June 6th 2019

Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses the use of immunotherapy in oligometastatic non–small cell lung cancer.

Dr. Ready on the Benefit of PD-L1 Inhibition in SCLC

June 5th 2019

Neal E. Ready, MD, PhD, professor of medicine, Duke University School of Medicine, member, Duke Cancer Institute, discusses the benefit of PD-L1 inhibition in small cell lung cancer.

Atezolizumab Boosts Survival in Patients With NSCLC, Liver Mets

June 3rd 2019

Patients with non–small cell lung cancer and baseline liver metastases had improved progression-free survival and overall survival with the addition of immunotherapy to bevacizumab and a chemotherapy doublet.

Preoperative Immunotherapy Sends Positive Signals in 2 NSCLC Studies

June 3rd 2019

Neoadjuvant immunotherapy demonstrated substantial activity with a favorable toxicity profile in findings from 2 studies of patients with operable early-stage non–small cell lung cancer reported at the 2019 ASCO Annual Meeting.

Pembrolizumab OS Rates Continue to Impress in NSCLC at 5 Years

June 1st 2019

After 5 years, newly diagnosed patients with advanced non–small cell lung cancer demonstrated an overall survival (OS) rate of 23.2% from treatment with pembrolizumab monotherapy and previously treated patients had an OS rate of 15.5%.

Dr. Langer on the Benefit of Durvalumab in Stage III NSCLC

May 29th 2019

Corey J. Langer, MD, director, Thoracic Oncology, Abramson Cancer Center, professor of medicine, Perelman School of Medicine, University of Pennsylvania, discusses the impact of durvalumab in stage III non–small cell lung cancer.

Pembrolizumab Shows Promise for Unmet Need in NMIBC

May 22nd 2019

Arjun V. Balar, MD, highlights the KEYNOTE-057 study findings and provided insight into the role of immunotherapy in bladder cancer.

Dr. Balar on Biomarkers of Immunotherapy Response in Bladder Cancer

May 22nd 2019

Arjun V. Balar, MD, assistant professor, Department of Medicine, director, Genitourinary Medical Oncology Program, NYU Langone's Perlmutter Cancer Center, discusses biomarkers of immunotherapy response in patients with bladder cancer.

Dr. Nadler on the Impact of Immunotherapy in Squamous NSCLC

May 20th 2019

Eric S. Nadler, MD, medical oncologist, Baylor University Medical Center, medical director, US Oncology Health Informatics and Internet Technology, discusses the impact of immunotherapy in squamous non–small cell lung cancer.

Dr. Whitman on Expanding the Benefit of Immunotherapy in Solid Tumors

May 17th 2019

Eric Whitman, MD, medical director of Atlantic Health System Cancer Care, Atlantic Health System, discusses ways to expand the benefit of immunotherapy in non-immunogenic solid tumors.

Pembrolizumab Approval in Squamous NSCLC Expands Treatment Arsenal

May 17th 2019

Viola W. Zhu, MD, PhD, explains how the use of immunotherapy has improved survival for patients with advanced squamous cell non–small cell lung cancer.

Dr. Sonpavde on Key Data With Immunotherapy in Metastatic Bladder Cancer

May 17th 2019

Guru P. Sonpavde, MD, director, Bladder Cancer, and physician, Dana-Farber Cancer Institute, discusses key data with immunotherapy in metastatic bladder cancer.

FDA Approves Avelumab/Axitinib for Frontline RCC

May 15th 2019

The FDA has approved the combination of avelumab and axitinib for the frontline treatment of patients with advanced renal cell carcinoma.

RCC Paradigm Continues to Rapidly Develop With TKI/IO Combos

May 13th 2019

Bradley McGregor, MD, speaks about the various data that have emerged in renal cell carcinoma with combinations of immunotherapy, TKIs, and how he chooses between the available treatments for his patients.

The Future of HCC Management

May 13th 2019

The TARE IO and TACE IO Combination Therapies

May 13th 2019

The CheckMate 9DX and EMERALD 1 and 2 Trials

May 13th 2019

Systemic Plus Locoregional Combination Therapy in HCC

May 13th 2019

Next Steps in Bladder Cancer Include Chemoimmunotherapy, Targeted Agents, and ADCs

May 9th 2019

Guru Sonpavde, MD, discusses the current use of immunotherapy and the numerous strategies in development in bladder cancer.

Dr. Sznol on Patient Selection for Combination Therapy in mRCC

May 9th 2019

Mario Sznol, MD, professor of medicine, co-director, Yale SPORE in Skin Cancer, Yale Cancer Center, discusses patient selection for combination therapy in metastatic renal cell carcinoma.